New insights into the biology of multiple myeloma (MM) are continually emerging. In this interview, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, covers what is known about Monoclonal Gammopathy of Undetermined Significance (MGUS) and clonal succession in MM. Dr Kaiser then considers whether this could be targeted, particularly in terms of predicting disease progression. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
Can genetic abnormalities be targeted in MM?
